Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cureus
Clinical practice observations of AVN following hip injury where non-adherence to activity restrictions was a contributing factor highlight the intersection of medication effects and behavioral challenges in ADHD patients.
Orthopedics/Sports Medicine July 23rd 2025
Verywell Mind
Clinical trials demonstrate bupropion effectiveness at 150-450mg daily for ADHD symptom reduction, with extended-release formulations improving medication adherence through once-daily dosing.
Family Medicine/General Practice June 17th 2025
MedCentral
Unacceptable levels of N-nitroso atomoxetine, a potential carcinogen, were found in multiple atomoxetine batches, according to the FDA.
Clinical Pharmacology April 1st 2025
Psych Congress Network
Methylphenidate significantly improved participants’ driving performance by reducing lane weaving and speed variation.
Clinical Pharmacology February 21st 2025
Medical News Today (MNT)
Analysis of more than 30,000 adult ADHD patients reveals significant increases in risk across 13 medical conditions, suggesting the need for comprehensive care protocols beyond standard ADHD management.
Pediatrics February 12th 2025
Analysis of more than 16.6 million pregnancies shows no significant increase in adverse outcomes for women maintaining methylphenidate or atomoxetine treatment during pregnancy.
Neurology January 22nd 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS